419 related articles for article (PubMed ID: 27814471)
21. Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry.
Mols F; Beijers AJ; Vreugdenhil G; Verhulst A; Schep G; Husson O
J Cancer Surviv; 2015 Sep; 9(3):512-22. PubMed ID: 25876556
[TBL] [Abstract][Full Text] [Related]
22. The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry.
Beijers AJ; Oerlemans S; Mols F; Eurelings M; Minnema MC; Vreugdenhil A; van de Poll-Franse LV
Ann Hematol; 2017 Apr; 96(4):653-663. PubMed ID: 28116479
[TBL] [Abstract][Full Text] [Related]
23. In Search of a Gold Standard Patient-Reported Outcome Measure for Use in Chemotherapy- Induced Peripheral Neuropathy Clinical Trials.
Smith EML; Knoerl R; Yang JJ; Kanzawa-Lee G; Lee D; Bridges CM
Cancer Control; 2018; 25(1):1073274818756608. PubMed ID: 29480026
[TBL] [Abstract][Full Text] [Related]
24. Physical function as a predictor of chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer.
Lin KY; Chen PS; Lin CF
BMC Gastroenterol; 2024 May; 24(1):154. PubMed ID: 38711006
[TBL] [Abstract][Full Text] [Related]
25. Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment - oxaliplatin subscale: a prospective cohort study.
Gu Z; Chen C; Gu J; Song Z; Wei G; Cai G; Shu Q; Zhu L; Zhu W; Deng H; Li S; Chen A; Yin Y; Wu Q; Zhu H; Li G; Dai A; Huo J
BMC Cancer; 2023 Nov; 23(1):1109. PubMed ID: 37964212
[TBL] [Abstract][Full Text] [Related]
26. Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life.
Balayssac D; Kerckhove N; Selvy M; Pereira B; Gonneau C; Pétorin C; Vimal-Baguet A; Melnikov S; Kullab S; Hebbar M; Bouché O; Slimano F; Bourgeois V; Lebrun-Ly V; Thuillier F; Mazard T; Tavan D; Benmammar KE; Monange B; Ramdani M; Péré-Vergé D; Huet-Penz F; Bedjaoui A; Genty F; Leyronnas C; Pezet D; Martin V
Support Care Cancer; 2024 Jun; 32(7):427. PubMed ID: 38869647
[TBL] [Abstract][Full Text] [Related]
27. Reliability and validity of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to assess Chemotherapy-induced peripheral neuropathy.
Kim HY; Kang JH; Youn HJ; So HS; Song CE; Chae SY; Jung SH; Kim SR; Kim JY
J Korean Acad Nurs; 2014 Dec; 44(6):735-42. PubMed ID: 25608551
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20).
Kieffer JM; Postma TJ; van de Poll-Franse L; Mols F; Heimans JJ; Cavaletti G; Aaronson NK;
Qual Life Res; 2017 Nov; 26(11):2999-3010. PubMed ID: 28634676
[TBL] [Abstract][Full Text] [Related]
29. Effect of Exercise on Taxane Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Randomized Controlled Trial.
Bland KA; Kirkham AA; Bovard J; Shenkier T; Zucker D; McKenzie DC; Davis MK; Gelmon KA; Campbell KL
Clin Breast Cancer; 2019 Dec; 19(6):411-422. PubMed ID: 31601479
[TBL] [Abstract][Full Text] [Related]
30. Association of electrochemical skin conductance with neuropathy in chemotherapy-treated patients.
Mahfouz FM; Park SB; Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; King T; Goldstein D; Mizrahi D
Clin Auton Res; 2022 Dec; 32(6):497-506. PubMed ID: 36129622
[TBL] [Abstract][Full Text] [Related]
31. Reflexology in the management of chemotherapy induced peripheral neuropathy: A pilot randomized controlled trial.
Kurt S; Can G
Eur J Oncol Nurs; 2018 Feb; 32():12-19. PubMed ID: 29353627
[TBL] [Abstract][Full Text] [Related]
32. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.
Cheng HL; Lopez V; Lam SC; Leung AKT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; De Ng TR; Suen LKP; Chan CW; Yorke J; Molassiotis A
Health Qual Life Outcomes; 2020 Jul; 18(1):246. PubMed ID: 32703223
[TBL] [Abstract][Full Text] [Related]
33. Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial.
Shinde SS; Seisler D; Soori G; Atherton PJ; Pachman DR; Lafky J; Ruddy KJ; Loprinzi CL
Support Care Cancer; 2016 Feb; 24(2):547-553. PubMed ID: 26155765
[TBL] [Abstract][Full Text] [Related]
34. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
35. IMPACT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY ON THE QUALITY OF LIFE IN CANCER PATIENTS.
Novak M; Miličević J; Bišof V
Acta Clin Croat; 2022 Mar; 61(1):52-61. PubMed ID: 36530966
[TBL] [Abstract][Full Text] [Related]
36. The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure.
Lavoie Smith EM; Haupt R; Kelly JP; Lee D; Kanzawa-Lee G; Knoerl R; Bridges C; Alberti P; Prasertsri N; Donohoe C
Oncol Nurs Forum; 2017 Sep; 44(5):580-588. PubMed ID: 28820525
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry.
Mols F; Beijers T; Lemmens V; van den Hurk CJ; Vreugdenhil G; van de Poll-Franse LV
J Clin Oncol; 2013 Jul; 31(21):2699-707. PubMed ID: 23775951
[TBL] [Abstract][Full Text] [Related]
38. Assessment of chemotherapy-induced peripheral neuropathy using the LDIFLARE technique: a novel technique to detect neural small fiber dysfunction.
Sharma S; Venkitaraman R; Vas PR; Rayman G
Brain Behav; 2015 Jul; 5(7):e00354. PubMed ID: 26221574
[TBL] [Abstract][Full Text] [Related]
39. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
[TBL] [Abstract][Full Text] [Related]
40. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States.
Nolte S; Liegl G; Petersen MA; Aaronson NK; Costantini A; Fayers PM; Groenvold M; Holzner B; Johnson CD; Kemmler G; Tomaszewski KA; Waldmann A; Young TE; Rose M;
Eur J Cancer; 2019 Jan; 107():153-163. PubMed ID: 30576971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
